
Brandon Couillard
Stock Analyst at Wells Fargo
(4.94)
# 163
Out of 5,189 analysts
714
Total ratings
63.8%
Success rate
19.1%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIO Bio-Rad Laboratories | Rated: Hold | n/a | $358.90 | - | 58 | Sep 29, 2026 | |
| BLLN BillionToOne | Rated: Hold | n/a | $89.92 | - | 7 | Sep 29, 2026 | |
| BRKR Bruker | Rated: Hold | n/a | $56.46 | - | 41 | Sep 29, 2026 | |
| CDNA CareDx | Rated: Hold | n/a | $70.00 | - | 12 | Sep 29, 2026 | |
| DHR Danaher | Rated: Hold | n/a | $220.36 | - | 54 | Sep 29, 2026 | |
| GH Guardant Health | Rated: Hold | n/a | $145.83 | - | 10 | Sep 29, 2026 | |
| MLAB Mesa Laboratories | Rated: Hold | n/a | $127.93 | - | 16 | Sep 29, 2026 | |
| MRVI Maravai LifeSciences Holdings | Rated: Hold | n/a | $6.98 | - | 13 | Sep 29, 2026 | |
| MTD Mettler-Toledo International | Rated: Hold | n/a | $1,666.88 | - | 26 | Sep 29, 2026 | |
| MYGN Myriad Genetics | Rated: Hold | n/a | $5.46 | - | 32 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $273.40 | - | 7 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $145.22 | - | 39 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $45.46 | - | 16 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $615 | $669.54 | -8.15% | 42 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $72.67 | -14.68% | 6 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $165 → $160 | $170.38 | -6.09% | 55 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $355 → $370 | $440.45 | -16.00% | 29 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $190 → $180 | $163.81 | +9.88% | 29 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $14 | $14.84 | -5.66% | 18 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $17 | $19.05 | n/a | 4 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $88 → $81 | $83.52 | n/a | 21 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $38 | $8.29 | n/a | 25 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $23 | $22.91 | n/a | 6 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $305 → $325 | $155.17 | n/a | 43 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $261.51 | n/a | 26 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $11 | $2.12 | n/a | 2 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $26 | $1.01 | n/a | 7 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $16 → $15 | $3.46 | n/a | 20 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $280 → $300 | $212.78 | n/a | 17 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3.5 → $4.5 | $1.57 | n/a | 16 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $1.75 | $0.2608 | n/a | 11 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $116 | $60.41 | n/a | 1 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $26 | $49.30 | n/a | 5 | Nov 22, 2016 |
Bio-Rad Laboratories
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $358.90
Upside: -
BillionToOne
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $89.92
Upside: -
Bruker
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $56.46
Upside: -
CareDx
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $70.00
Upside: -
Danaher
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $220.36
Upside: -
Guardant Health
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $145.83
Upside: -
Mesa Laboratories
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $127.93
Upside: -
Maravai LifeSciences Holdings
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $6.98
Upside: -
Mettler-Toledo International
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $1,666.88
Upside: -
Myriad Genetics
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $5.46
Upside: -
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $273.40
Upside: -
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $145.22
Upside: -
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $45.46
Upside: -
Jul 23, 2026
Rated: Buy
Price Target: $615
Current: $669.54
Upside: -8.15%
Jun 26, 2026
Reiterated: Buy
Price Target: $62
Current: $72.67
Upside: -14.68%
May 28, 2026
Reiterated: Buy
Price Target: $165 → $160
Current: $170.38
Upside: -6.09%
May 14, 2026
Reiterated: Hold
Price Target: $355 → $370
Current: $440.45
Upside: -16.00%
Feb 25, 2026
Reiterated: Buy
Price Target: $190 → $180
Current: $163.81
Upside: +9.88%
Feb 13, 2026
Reiterated: Buy
Price Target: $16 → $14
Current: $14.84
Upside: -5.66%
Mar 13, 2024
Reiterated: Buy
Price Target: $21 → $17
Current: $19.05
Upside: n/a
Mar 6, 2024
Reiterated: Hold
Price Target: $88 → $81
Current: $83.52
Upside: n/a
Feb 29, 2024
Reiterated: Buy
Price Target: $36 → $38
Current: $8.29
Upside: n/a
Feb 9, 2024
Downgraded: Hold
Price Target: $32 → $23
Current: $22.91
Upside: n/a
Feb 1, 2024
Reiterated: Buy
Price Target: $305 → $325
Current: $155.17
Upside: n/a
Aug 29, 2022
Reiterated: Buy
Price Target: $200
Current: $261.51
Upside: n/a
May 4, 2022
Reiterated: Buy
Price Target: $13 → $11
Current: $2.12
Upside: n/a
Jun 18, 2021
Rated: Buy
Price Target: $26
Current: $1.01
Upside: n/a
Aug 6, 2020
Rated: Hold
Price Target: $16 → $15
Current: $3.46
Upside: n/a
May 18, 2020
Reiterated: Buy
Price Target: $280 → $300
Current: $212.78
Upside: n/a
Aug 8, 2018
Reiterated: Hold
Price Target: $3.5 → $4.5
Current: $1.57
Upside: n/a
Jul 27, 2018
Reiterated: Buy
Price Target: $2 → $1.75
Current: $0.2608
Upside: n/a
May 31, 2017
Reiterated: Buy
Price Target: $116
Current: $60.41
Upside: n/a
Nov 22, 2016
Reiterated: Hold
Price Target: $26
Current: $49.30
Upside: n/a